论文部分内容阅读
目的探讨复发肺结核的耐药情况,评估复发肺结核的疗效。方法选取本院2014年5月至2016年5月的复发肺结核者200例的临床资料,所有画着均给予罗氏培养基给予结核分枝杆菌基因扩增实验,分析其耐药性;并监测其化疗方案实施过程,分析临床疗效。结果总有耐药率为45.5%;异烟肼耐药率、链霉素耐药率、阿米卡星耐药率以及利福平耐药率分别为11.5%、16.0%、6.5%、11.5%,治愈率为51.2%,接受治疗率为85.0%。结论复发结核者的耐药率相对较高,故在复发肺结核中应做好相关的耐药结果分析,给予耐药性较小的临床药物。
Objective To investigate the drug resistance of recurrent pulmonary tuberculosis and evaluate the curative effect of recurrent pulmonary tuberculosis. Methods The clinical data of 200 patients with recurrent tuberculosis from May 2014 to May 2016 in our hospital were selected. All the patients were given Roche medium to give Mycobacterium tuberculosis gene amplification test to analyze its drug resistance; Chemotherapy program implementation process, analysis of clinical efficacy. The total resistance rate was 45.5%. The isoniazid resistance, streptomycin resistance, amikacin resistance and rifampin resistance were 11.5%, 16.0%, 6.5%, 11.5 %, The cure rate was 51.2% and the treatment rate was 85.0%. Conclusions The drug resistance rate of recurrent tuberculosis is relatively high, so the related drug resistance results should be analyzed in the recurrent pulmonary tuberculosis, and the clinical drug with less drug resistance should be given.